🚀 VC round data is live in beta, check it out!
Tango Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tango Therapeutics and similar public comparables like Corvus Pharma, Vir Biotechnology, Iovance Biotherapeutics, ORIC Pharmaceuticals and more.
Tango Therapeutics Overview
About Tango Therapeutics
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Founded
2020
HQ
Employees
155
Website
Sectors
Financials (LTM)
EV
$1B
Tango Therapeutics Financials
Tango Therapeutics reported last 12-month revenue of $50M and negative EBITDA of ($125M).
In the same LTM period, Tango Therapeutics generated $50M in gross profit, ($125M) in EBITDA losses, and had net loss of ($119M).
Revenue (LTM)
Tango Therapeutics P&L
In the most recent fiscal year, Tango Therapeutics reported revenue of $62M and EBITDA of ($109M).
Tango Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $50M | XXX | $62M | XXX | XXX | XXX |
| Gross Profit | $50M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($125M) | XXX | ($109M) | XXX | XXX | XXX |
| EBITDA Margin | (249%) | XXX | (175%) | XXX | XXX | XXX |
| EBIT Margin | (255%) | XXX | (178%) | XXX | XXX | XXX |
| Net Profit | ($119M) | XXX | ($102M) | XXX | XXX | XXX |
| Net Margin | (235%) | XXX | (163%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tango Therapeutics Stock Performance
Tango Therapeutics has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Tango Therapeutics' stock price is $11.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $-0.75 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTango Therapeutics Valuation Multiples
Tango Therapeutics trades at 27.4x EV/Revenue multiple, and (11.0x) EV/EBITDA.
EV / Revenue (LTM)
Tango Therapeutics Financial Valuation Multiples
As of March 21, 2026, Tango Therapeutics has market cap of $2B and EV of $1B.
Equity research analysts estimate Tango Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tango Therapeutics has a P/E ratio of (12.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 27.4x | XXX | 22.2x | XXX | XXX | XXX |
| EV/EBITDA | (11.0x) | XXX | (12.7x) | XXX | XXX | XXX |
| EV/EBIT | (10.8x) | XXX | (12.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 27.4x | XXX | — | XXX | XXX | XXX |
| P/E | (12.6x) | XXX | (14.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tango Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tango Therapeutics Margins & Growth Rates
Tango Therapeutics' revenue in the last 12 month declined by (87%).
Tango Therapeutics' revenue per employee in the last FY averaged $0.3M.
Tango Therapeutics' rule of 40 is (335%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tango Therapeutics' rule of X is (465%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Tango Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (87%) | XXX | (88%) | XXX | XXX | XXX |
| EBITDA Margin | (249%) | XXX | (175%) | XXX | XXX | XXX |
| EBITDA Growth | 54% | XXX | 70% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (335%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (465%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 84% | XXX | 67% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 269% | XXX | 212% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 278% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tango Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Corvus Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Vir Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Iovance Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| ORIC Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Chongqing Genrix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tango Therapeutics M&A Activity
Tango Therapeutics acquired XXX companies to date.
Last acquisition by Tango Therapeutics was on XXXXXXXX, XXXXX. Tango Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tango Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTango Therapeutics Investment Activity
Tango Therapeutics invested in XXX companies to date.
Tango Therapeutics made its latest investment on XXXXXXXX, XXXXX. Tango Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tango Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tango Therapeutics
| When was Tango Therapeutics founded? | Tango Therapeutics was founded in 2020. |
| Where is Tango Therapeutics headquartered? | Tango Therapeutics is headquartered in United States. |
| How many employees does Tango Therapeutics have? | As of today, Tango Therapeutics has over 155 employees. |
| Who is the CEO of Tango Therapeutics? | Tango Therapeutics' CEO is Malte Peters. |
| Is Tango Therapeutics publicly listed? | Yes, Tango Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Tango Therapeutics? | Tango Therapeutics trades under TNGX ticker. |
| When did Tango Therapeutics go public? | Tango Therapeutics went public in 2021. |
| Who are competitors of Tango Therapeutics? | Tango Therapeutics main competitors are Corvus Pharma, Vir Biotechnology, Iovance Biotherapeutics, ORIC Pharmaceuticals. |
| What is the current market cap of Tango Therapeutics? | Tango Therapeutics' current market cap is $2B. |
| What is the current revenue of Tango Therapeutics? | Tango Therapeutics' last 12 months revenue is $50M. |
| What is the current revenue growth of Tango Therapeutics? | Tango Therapeutics revenue growth (NTM/LTM) is (87%). |
| What is the current EV/Revenue multiple of Tango Therapeutics? | Current revenue multiple of Tango Therapeutics is 27.4x. |
| Is Tango Therapeutics profitable? | No, Tango Therapeutics is not profitable. |
| What is the current EBITDA of Tango Therapeutics? | Tango Therapeutics has negative EBITDA and is not profitable. |
| What is Tango Therapeutics' EBITDA margin? | Tango Therapeutics' last 12 months EBITDA margin is (249%). |
| What is the current EV/EBITDA multiple of Tango Therapeutics? | Current EBITDA multiple of Tango Therapeutics is (11.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.